Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results ...

Sanofi reiterated its financial forecast for the remainder of the year, but new, long-range guidance for 2024 and 2025 implies financial results lower than current analyst estimates.

Shares of Sanofi (NASDAQ: SNY) were up 10.20% the week ended March 24, while Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) finished with a gain of 9.68%, following promising news about the ...

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent(dupilumab) in treating moderate-to-severe atopic dermatitis (AD) in ...

PARIS, Jan 30 (Reuters) - Healthcare companies Sanofi (SASY.PA), opens new tab and Regeneron (REGN.O), opens new tab said on Monday that their Dupixent product had won approval from the European ...

Additionally, Regeneron will pay Sanofi $900 million upfront within 10 days of the deal’s start date as well as a $100 million “development milestone payment” when it receives the first ...

Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD Drug is cleared for 300,000 U.S. patients with a form of the lung disease driven by eosinophils Manage alerts for this article ...

Sanofi is selling a stake in Regeneron Pharmaceuticals Inc. valued at about $13 billion, giving the French drug giant more firepower to invest in fast-growing fields such as cancer.

Sanofi boosted its stake in Regeneron, though the French drug maker has said it doesn't plan to buy the research and development drug company. French Drug Maker Now Holds About 22.5% of Regeneron ...